Financial Shenanigans

Financial Shenanigans

Daqo's reported numbers look like a faithful, if unflattering, picture of a deep-cyclical Chinese commodity producer at the bottom of a polysilicon glut. There is no restatement, no auditor qualification, no admitted misconduct, and the balance sheet still carries roughly $2.0B of cash and term deposits with zero bank debt. The forensic concerns are concentrated in three places: family-and-parent-group governance that limits independent challenge, judgment-driven impairment timing that produced a clean 2025 P&L despite continued ASP weakness, and a sharp jump in receivables in 2025 against a 35% revenue decline that is paired for the first time with an explicit "long-aged receivables" credit-loss allowance. The single data point that would most change this assessment is the FY2026 receivables and credit-loss line: another build with another allowance bump would push the grade into Elevated.

The Forensic Verdict

13-Category Shenanigans Scorecard

Breeding Ground

The structural conditions favor aggressive reporting more than the reported numbers themselves do. Three lines of concern overlap: founder/family control, parent-group entanglement, and a controlled-subsidiary listing in Shanghai that creates a permanent tax-and-dividend channel between the Cayman parent and Chinese-listed Xinjiang Daqo (Daqo Cayman owns roughly 71.66% of Xinjiang Daqo per third-party reporting).

The Compensation Committee structure is the single hardest item to defend. The chair is a senior officer of the parent Daqo Group, the company itself does not claim he is independent, and a committee that meets only via written consent during a year with $55.8M of SBC and a 30-year-old family member promotion to Deputy CEO is exactly the kind of structure where outside investors would expect more friction.

Earnings Quality

Reported earnings track the polysilicon cycle with credible fidelity, but the quality of the bottom line is rising-and-falling on impairment judgments, an inventory write-down decision, and a credit-loss allowance that arrived only after receivables had aged.

The FY2025 line is the forensic one: revenue down 35.3% to $665.4M, and gross receivables up roughly 146% to $135.5M. Management discloses "uncertainties in recoverability of long-aged receivables" and books a $19.3M expected credit loss for the second consecutive year (zero in 2023, $18.1M in 2024). The combination of an end-of-cycle volume push (Q4 ASP rebound disclosed; full-year ASP still down 7.3%) plus an aging receivable book plus a fresh credit-loss reserve is consistent with extending credit to keep customers buying — a yellow flag, not a red one, but worth quarterly tracking.

The 2024 charges concentrated three judgment items in the same loss year: $175.6M of long-lived asset impairment on older polysilicon lines, $108M of Q2 non-cash inventory write-down (cost above market), and the first-ever $18.1M credit-loss allowance. In 2025 the long-lived asset test was reset to zero, with management citing a polysilicon ASP "rebound" — but the full-year 2025 ASP of $5.25/kg was 7.3% below the 2024 average of $5.66/kg. The impairment reset is defensible if Q4 ASP and 2026 expectations support the carrying value, but it is not symmetric with what the income statement shows.

SBC is now the single largest cushion under operating cash flow. In 2025, the $55.8M SBC add-back exceeds the $49.7M reported CFO, meaning underlying operating cash before SBC was negative.

Cash Flow Quality

Across the cycle, headline CFO is faithful in direction but flatters at the boom-bust transition. The FY2023 CFO of $1.62B was magnified by a roughly $1.0B receivables collapse as sales price fell and customers (apparently) accelerated payments after the late-2022 deferral build; FY2025 CFO is barely positive and is roughly equal to the SBC add-back.

Two periods break the normal "CFO ≈ NI" pattern that a forensic reader looks for:

1. FY2023: consolidated NI $653M, CFO $1,616M, ratio 2.48x. The gap is overwhelmingly the $1.0B drawdown in receivables from $1,131.6M to $116.4M as the polysilicon market normalized. This is recoverable cash, not a manipulation, but it is a non-recurring tailwind that ended in 2024.
2. FY2024–FY2025: CFO turned negative in 2024 (-$435M) and printed only $50M in 2025. Management's own prior-period CFO strength was funded by the working-capital release; once the release ended, CFO collapsed.

The FY2023 swing of roughly +$670M of working-capital contribution is the cleanest single illustration of why CFO/NI was 2.48x that year and 0.97x in 2024.

There is no acquisition activity to mask, which is helpful. The total $1.4B economic capex during the build phase is visible in PPE — Property, Plant & Equipment grew from $1.0B (FY2020) to $3.5B (FY2024), and management discloses that $279M of FY2025 PPE additions remained unpaid at year-end (in payables), meaning FY2025 economic capex is meaningfully larger than the $173M reported as cash capex once the closing payables movement is incorporated.

Metric Hygiene

Daqo's headline disclosures are fairly disciplined for a Chinese ADR — they re-state ASP, sales volume, production volume, capacity, and per-kilo production cost ($6.61/kg in 2025) every quarter, on the same definitions, with the same divisors. The most-aggressive metric is the company's "Adjusted EBITDA," which is calculated by adding back depreciation, amortization, interest, taxes, SBC, and non-cash impairments — the typical "EBITDA-A" recipe. The reconciliation is published in each earnings release, so investors can flip back to GAAP without effort.

The notable miss is that DSO and inventory days are not in management's headline KPI panel even though receivables and inventory carry the most underwriting risk in a glut. An investor who relies only on management's deck will not see the FY2025 receivable build until they read the balance sheet.

What to Underwrite Next

The Watch grade hinges on five disclosures that the next 20-F or quarterly release will resolve.